These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28543368)

  • 1. Primary signet-ring cell/histiocytoid carcinoma of the eyelid expressing androgen receptors and treated with bicalutamide.
    Sakamoto K; Ito T; Tanioka F; Fukamizu H; Tokura Y
    J Dermatol; 2017 Sep; 44(9):e230-e231. PubMed ID: 28543368
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature.
    Arce-Salinas C; Riesco-Martinez MC; Hanna W; Bedard P; Warner E
    J Clin Oncol; 2016 Feb; 34(4):e21-4. PubMed ID: 24888812
    [No Abstract]   [Full Text] [Related]  

  • 3. Primary signet-ring cell/histiocytoid carcinoma of the eyelid: a clinicopathologic study of 5 cases and review of the literature.
    Requena L; Prieto VG; Requena C; Sarasa JL; Manzano R; Seco M; Rütten A; Kazakov DV; Cerroni L; Kutzner H
    Am J Surg Pathol; 2011 Mar; 35(3):378-91. PubMed ID: 21317710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bicalutamide].
    Taéron C
    Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
    [No Abstract]   [Full Text] [Related]  

  • 5. [Bicalutamide].
    Kotake T
    Nihon Rinsho; 2000 Jul; 58 Suppl():216-22. PubMed ID: 11022717
    [No Abstract]   [Full Text] [Related]  

  • 6. Bicalutamide with radiotherapy for prostate cancer.
    Brower V
    Lancet Oncol; 2017 Mar; 18(3):e141. PubMed ID: 28190764
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial comment to Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
    Yoshida T
    Int J Urol; 2013 Jul; 20(7):714-5. PubMed ID: 23216631
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral bicalutamide for female pattern hair loss: A pilot study.
    Fernandez-Nieto D; Saceda-Corralo D; Rodrigues-Barata R; Hermosa-Gelbard A; Moreno-Arrones O; Jimenez-Cauhe J; Ortega-Quijano D; Vano-Galvan S
    Dermatol Ther; 2019 Nov; 32(6):e13096. PubMed ID: 31579984
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
    Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
    Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photosensitive drug eruption induced by bicalutamide within the UVB action spectrum.
    Sasada K; Sakabe J; Tamura A; Kasuya A; Shimauchi T; Ito T; Hirakawa S; Tokura Y
    Eur J Dermatol; 2012; 22(3):402-3. PubMed ID: 22503957
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Garnick MB
    BJU Int; 2012 Oct; 110(8):1155. PubMed ID: 22369480
    [No Abstract]   [Full Text] [Related]  

  • 12. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M; Lacombe L; Fradet Y
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial [
    Boers J; Venema CM; de Vries EFJ; Hospers GAP; Boersma HH; Rikhof B; Dorbritz C; Glaudemans AWJM; Schröder CP
    Eur J Cancer; 2021 Feb; 144():151-161. PubMed ID: 33341447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
    Lau YK; Chadha MK; Litwin A; Trump DL
    J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative.
    Jia AY; Spratt DE
    Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):316-319. PubMed ID: 35569476
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-androgen for myoepithelial tumor: a potent therapy yet a potential misleader.
    Hijab A; Taha T; Charas T; Bar-Sela G; Stein P; Agbarya A
    Anticancer Drugs; 2022 Jan; 33(1):e747-e751. PubMed ID: 34387605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bicalutamide.
    Prescrire Int; 2007 Apr; 16(88):67. PubMed ID: 17458049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signet-ring cell/histiocytoid carcinoma of the eyelid: a case report and review of the literature.
    Tanboon J; Uiprasertkul M; Luemsamran P
    Am J Dermatopathol; 2013 Feb; 35(1):e1-5. PubMed ID: 22885554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary signet ring cell carcinoma of the eyelid in a young woman.
    Khoramnia R; Mayer C; Glaser E; Weirich G
    Eye (Lond); 2011 Oct; 25(10):1380-2. PubMed ID: 21738227
    [No Abstract]   [Full Text] [Related]  

  • 20. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.